Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
Anuja Pandit,
Nirav Bhalani,
B.L. Shashi Bhushan,
Parshottam Koradia,
Shweta Gargiya,
Vinay Bhomia,
Kevinkumar Kansagra
Affiliations
Anuja Pandit
National Cancer Institute, Badsa, Jhajjar, Haryana 124105, India
Nirav Bhalani
Rhythm Heart Institute, Near Siddharth Bungalows, Sama Savli Road, Vadodara 390022, Gujarat, India
B.L. Shashi Bhushan
Victoria Hospital, Bangalore Medical College & Research Institute, Fort K R Road, Bangalore Urban, Karnataka 560002, India
Parshottam Koradia
BAPS Pramukh Swami Hospital, Shri Pramukh Swami Maharaj Marg, Adajan Char Road, Adajan, Surat 395009, Gujarat, India
Shweta Gargiya
Tapan Research Centre, Basement Tapan Hospital Nr. Platinum Hall, Anandnagar Cross Road Satellite, Ahmedabad 380015, Gujarat, India
Vinay Bhomia
Sanjivani Super Speciality Hospital, 1, Uday Park Society, Nr. Sunrise Park, Vastrapur, Ahmedabad 380015, Gujarat, India
Kevinkumar Kansagra
Zydus Research Centre, Clinical R & D, Cadila Healthcare Limited, Sarkhej-Bavla N. H. No. 8 A, Moraiya, Ahmedabad 382213, Gujarat, India; Corresponding author: Kevinkumar Kansagra.
